Waheed Nadia
Chief Medical Officer
Waheed Nadia has filed 4 SEC Form 4 filings (4 transaction rows) across 1 company, with disclosures dating back to 2026. 4 of those filings fall inside the rolling window. Most recent filing: Jun 5, 2026.
On the most recent filing, Waheed Nadia is listed as Chief Medical Officer at OCULAR THERAPEUTIX, INC. Inside the rolling window, Waheed Nadia reported no open-market purchases and 3 open-market sales totaling $221K in OCUL. The largest disclosed transaction in the window is a sale of 14,828 OCUL shares on Jun 3, 2026, worth $123K.
Companies traded
Other insiders at OCUL
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$221K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Waheed Nadia made?
Waheed Nadia has filed 4 SEC Form 4 filings (4 transaction rows) across 1 company since 2026.
Which companies does Waheed Nadia trade?
Waheed Nadia has filed SEC Form 4 disclosures for 1 company, including OCUL.
When was Waheed Nadia's most recent SEC Form 4 filing?
Waheed Nadia's most recent SEC Form 4 filing on Tracefour is dated Jun 5, 2026.
What is Waheed Nadia's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Waheed Nadia is listed as Chief Medical Officer.
What is Waheed Nadia's total buy and sell value in the current window?
Inside the rolling retention window, Waheed Nadia bought $0 and sold $221K based on SEC Form 4 filings.
What was Waheed Nadia's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 14,828 OCUL shares on 2026-06-03, worth $123K, per SEC Form 4 filings.